Fundraising FoxBain Capital Life Sciences — 2019 Investments
4 investments dated 2019 · listed companies and verified rows first · show all
Arcutis is a biopharmaceutical company focused on dermatology, developing treatments for immune-mediated skin diseases such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp psoriasis.
BiotechHealthtechMedical DevicesWestlake Village, US
Todd Franklin Watanabe(Executive Officer, Director)Alexander Asam(Director)Ricky Sun(Director)
BoardPatrick Heron(Director)inDaniel Estes(Director)inJonathan Silverstein(Director)
Co-investorsFrazier Life SciencesRA Capital
Savara is a biopharmaceutical company developing treatments for autoimmune pulmonary alveolar proteinosis (autoimmune PAP) and other rare lung diseases.
BiotechHealthtechMedical DevicesAustin, US
Matt Pauls(Chair of the Board of Directors and Chief Executive Officer)inMike Ciesla(Executive Officer)Badrul Chowdhury(Executive Officer)inSantosh J. Vetticaden(Executive Officer)Gregory D. Gorgas(Executive Officer)Patrick Keran(Executive Officer)
Co-investorsCentral Texas Angel NetworkGreen Park & Golf VenturesKeiretsu ForumMoore Venture PartnersNew Enterprise Associates (NEA)
Imperative Care develops medical technologies for treating stroke and other vascular diseases, aiming to address gaps across the patient care journey.
HealthtechMedical DevicesCampbell, US
Farhad Khosravi(Executive Officer, Director)Matthew Garrett(Executive Officer)inCharles Alpuche(Executive Officer)Scott Elliott(Executive Officer)in
BoardJames Rogers(Director)Stacy Enxing Seng(Director)
Board seatAndrew Hack· per SEC Form D
Co-investorsAscension VenturesCatalio Capital Management, LPDelos CapitalFemHealth VenturesLightstone Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.